KDIGO Guideline-Recommended Disease-Modifying Therapies for Cardiorenal Syndrome

Zusammenfassung

Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative Review ABSTRACT Abstract Substantial gaps exist between recommendations for guideline-directed medical therapy (GDMT) for chronic kidney disease (CKD) and its use in real-world clinical practice. This includes suboptimal dosing of renin-angiotensin system inhibitors (RASi), low uptake of sodium-glucose co-transporter 2 inhibitors (SGLT2i) for CKD, and low uptake and/or transient u

Kerninformationen

This includes suboptimal dosing of renin-angiotensin system inhibitors (RASi), low uptake of sodium-glucose co-transporter 2 inhibitors (SGLT2i) for CKD, and low uptake and/or transient use of potassium binders to manage RASi-induced hyperkalemia. Suboptimal RASi therapy deprives patients of the ful...

Despite clear clinical practice guidelines, there is a considerable gap between the recommendations for guideline-directed medical therapy (GDMT) for CKD and its implementation and adherence in real-world clinical practice. Barriers to optimal CKD management include a lack of disease awareness, limi...

The 2024 guideline now recommends drug classes such as sodium-glucose co-transporter 2 inhibitors (SGLT2i) as first-line therapy for most patients along with renin-angiotensin system inhibitors (RASi), nonsteroidal mineralocorticoid antagonists (ns-MRA) with proven kidney or cardiovascular benefit t...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen